News

NEHI Releases White Paper Describing New Metric to Measure Primary Medication Non-Adherence Using e-Prescribing Technology

Topics: Electronic prescriptions

To address the problem of primary medication non-adherence (PMN), the Network for Excellence in Health Innovation (NEHI) has released a white paper describing a new metric for measuring rates of PMN by monitoring electronic prescriptions.

Read More →

Assured Brand Naproxen tablets Recalled Due to Packaging Error

Topics: Over the counter, Patient safety, and Fda

Contract Packaging Resources of Greensboro, NC, a drug repackaging company, is voluntarily recalling nearly 12,000 boxes of Assured brand naproxen sodium tablets because some cartons contain bottles of 200 mg ibuprofen softgels instead, a press release posted to the Food and Drug Administration (FDA) website indicates. 

Read More →

Hospira Recalls One Lot of Lidocaine HCl for Injection Due to Particulate Matter

Topics: Compounding and Fda

Hospira, Inc, of Lake Forest, IL, has announced a voluntary nationwide recall of one lot of 1% Lidocaine HCl for Injection, USP, 10 mg per mL, 30 mL single-dose, preservative-free due to the presence of particulate matter. 

Read More →

California Requires Outsourcing Facilities to Be Registered as Pharmacies if Compounding or Dispensing Drug Within or Into the State

Topics: Compounding

The California Board of Pharmacy is requiring outsourcing facilities to be registered as pharmacies if compounding or dispensing drugs within or into the state.

Read More →

FDA Plans to Study Effect of Color, Shape, and Size of Generic Drugs on Patient Adherence

Topics: Medication therapy management and Fda

FDA has proposed a survey of patients and pharmacists to determine how the color, shape, and size of a drug product affect patient adherence rates, particularly for generic drugs. 

Read More →

NABP Issues Policy Statement Supporting the Pharmacist’s Role in Increasing Access to Opioid Overdose Reversal Drug

Topics: Patient safety and Prescription drug abuse

As the opioid overdose epidemic continues to take hundreds of lives each week, the National Association of Boards of Pharmacy® (NABP®) has issued a policy statement promoting an active role for pharmacists in expanding access to the opioid overdose reversal drug, naloxone. 

Read More →

NABP Seeks Nominations for 2015 Awards to be Presented at Annual Meeting

NABP invites you to nominate a colleague or board of pharmacy for a 2015 NABP award. 

Read More →

Pharmacy Robberies Plague Arizona, Other States, Says DEA

Topics: Diversion, Pharmacies, and Dea

Fueled by the prescription drug abuse epidemic, Arizona experienced the most pharmacy robberies in 2013 with 77 incidents, according to a report compiled by Drug Topics using Drug Enforcement Administration statistics. 

Read More →

FDA Orders New Jersey Company to Destroy Unapproved Drug Products

Topics: Fda

Federal authorities have ordered a New Jersey company to destroy its unapproved products and stop further manufacturing and distributing them until the drugs receive Food and Drug Administration (FDA) approval.

Read More →

FDA Warns Consumers, Health Care Professionals About Over-the-Counter Drug Products

Topics: Over the counter and Fda

FDA is advising consumers and health care professionals not to use Sit and Slim II, Dermatend Original, and Dermatend Ultra because the drug products are unapproved and could cause harm.

Read More →

NABP Issues Policy Statement Supporting the Pharmacist’s Role in Increasing Access to Opioid Overdose Reversal Drug

Topics: Pharmacists

As the opioid overdose epidemic continues to take hundreds of lives each week, the National Association of Boards of Pharmacy® (NABP®) has issued a policy statement promoting an active role for pharmacists in expanding access to the opioid overdose reversal drug, naloxone.

Read More →